Comprehensive Therapeutic Framework for ME/CFS
- Aug 26, 2025
- 5 min read
Updated: Apr 2
Clinician Guide: Built from CYNAERA Diagnostic Fingerprints™ + IACCI Terrain Logic + XR/CR Pharmacology Doctrine
Step 1. Diagnostic Fingerprints & Lab Anchors
Order baseline labs to guide phenotype and rule out mimics/emergencies:
Core Panel: CBC, CMP, ferritin, iron studies, B12, folate, vitamin D, ANA/ENA, CRP, ESR, thyroid panel (TSH, free T3, free T4, antibodies).
Add-ons by phenotype:
Autonomic → orthostatic vitals, norepinephrine supine/upright, aldosterone/renin.
Neuroinflammatory → migraine profile if available.
Pain-dominant → CK, magnesium, rheum panel.
Immune-reactivation → EBV, HHV-6, CMV, immunoglobulin subclasses.
MCAS → tryptase, histamine, prostaglandin D2, DAO.
Sleep → sleep study, actigraphy.
Step 2. Assign Phenotypes
1. Energy Dysregulation Axis
2. Autonomic & Circulatory Axis
3. Neuro-Immune & Sensory Axis
4. Hormonal & Endocrine Axis
5. Immune, Infection & Reactivation Axis
6. Sleep & Pain Axis
7. Social, Demographic & Access Constrained
Step 3. Universal Pharmacology Doctrine
Extended-release (XR/CR) formulations preferred wherever possible.
Start lower than standard minimum dose.
Titrate slowly: one variable every 7–14 days (longer in severe/MCAS).
Stop rules: discontinue if PEM worsens >2 weeks, HR <50, new MCAS flare, or intolerable side effects.
Severe ≠ high dose. The sicker the patient, the slower and lower the approach.
Step 4. Therapeutic Ladders by Phenotype
Tier 1: Foundational (OTC + Supplements)
Mito Protocol: CoQ10 (100–300 mg XR if available), acetyl-L-carnitine, NAD+, riboflavin, creatine.
Minerals: magnesium glycinate/threonate, electrolytes, potassium citrate (if renal labs safe).
Anti-inflammatory nutraceuticals: omega-3s, curcumin, quercetin, resveratrol.
Stop points: GI upset, bleeding risk, paradoxical insomnia/tachycardia.
Tier 2: PCP-Prescribable Medications
Autonomic (B)
Beta-blockers (prefer XR/CR): metoprolol succinate XR, propranolol LA. Start 12.5 mg XR daily.
Stop if HR <50, symptomatic hypotension, bronchospasm.
Fludrocortisone: 0.05–0.1 mg daily. Stop if edema, hypertension, hypokalemia.
Midodrine: 2.5–5 mg TID daytime. Stop if supine hypertension.
Ivabradine: 2.5 mg BID. Stop if bradycardia <50 or visual phenomena.
Neuroinflammatory (C)
Migraine prophylaxis (XR/CR): propranolol LA, amitriptyline XR, topiramate XR.
Neuropathic pain: pregabalin XR (start 25–50 mg nightly).
Stop points: sedation, paradoxical agitation, cognitive decline.
Immune-reactivation (E)
Low-Dose Naltrexone (LDN): start 0.5–1.5 mg nightly → titrate 3–4.5 mg.
Stop if vivid nightmares >2 weeks, insomnia, liver enzymes rise.
Tier 3: Specialist / Experimental Therapies
Immune / Antiviral
Valganciclovir, famciclovir, valacyclovir (divided dosing to mimic XR).
Stop if neutropenia, LFT elevations, no benefit at 6 months.
IVIG
1–2 g/kg monthly. Stop if severe reaction, thrombosis, renal impairment.
Pyridostigmine
30–60 mg BID. Stop if intolerable GI, fasciculations, bradycardia.
Emerging Therapies
Inspiritol (inhaled immunomodulator): investigational; early promise for neuroinflammatory + immune-reactivation phenotypes.
Stop if airway irritation, MCAS flares.
Tollovid (3CL protease inhibitor nutraceutical): considered in immune-reactivation phenotype, viral serology-positive patients.
Stop if GI upset, CYP drug interactions, cost burden.
Step 5. Environment & Flare Logic
Heat/humidity: prioritize autonomic treatments (XR beta-blockers, fludrocortisone, electrolytes).
Cold: support circulation (compression, fludrocortisone if safe).
Poor air quality / smoke: MCAS supports (antihistamines, cromolyn, filters).
Mold/home triggers: consider MCAS ladder, cholestyramine, environmental remediation.
Light/noise sensitivity: neuroimmune stabilizers (lamotrigine, memantine, riluzole).
Step 6. Abuse/Trauma Overlay
Screen all patients: care interference, environmental sabotage, med tampering.
If risk band ≥3:
XR/CR formulations preferred for steady coverage.
Pharmacy blister packs, direct delivery.
Single-variable titration every 7–14 days.
Private note segmentation in EHR.
Step 7. Stop Rules (Cross-Cutting)
Therapy-induced PEM: treat as dose-too-high, not drug failure.
New MCAS symptoms: pause, add H1/H2 support.
One change at a time. No polytrialing.
Objective check-ins: repeat CBC, CMP, ferritin, CRP, ESR after major drug changes.
Step 8. Escalation Boundaries
Advance to higher tiers only when:
Lower tier exhausted/tolerated.
Labs and phenotype support escalation.
Patient consent and monitoring in place.
Severe/bedbound patients should never be escalated aggressively.
Disclaimer
This framework is decision support only. It integrates CYNAERA Diagnostic Fingerprints™, Phenotyping, IACCI terrain logic, XR/CR pharmacology doctrine, and patient safety overlays. Final prescribing authority rests with the treating clinician.
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library and ME/CFS Library is also a great resource.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.
About the Author
Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.
Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.
Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™, IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.
Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.
Comments